American Heart Journal
Volume 148, Issue 2 , Pages 263-268 , August 2004

Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high-risk primary prevention: Rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial

  • Deepak L. Bhatt, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • Corresponding Author InformationReprint requests: Deepak L. Bhatt, MD, Cleveland Clinic Foundation, Department of Cardiovascular Medicine/Desk F25, 9500 Euclid Ave, Cleveland, OH 44195, USA.
    • ,
  • Eric J. Topol, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio, USA
    • ,
  • CHARISMA Executive Committee

      Affiliations

    • See Appendix for a complete list of the CHARISMA Executive Committee.

Received 7 December 2003 ,Accepted 29 March 2004.

References 

  1. Yusuf S, Reddy S, Ounpuu S, et al.  Global burden of cardiovascular diseases, I (general considerations, the epidemiologic transition, risk factors, and impact of urbanization). Circulation. 2001;104:2746–2753
  2. Yusuf S, Reddy S, Ounpuu S, et al.  Global burden of cardiovascular diseases, II (variations in cardiovascular disease by specific ethnic groups and geographic regions and prevention strategies). Circulation. 2001;104:2855–2864
  3. Smith SC, Greenland P, Grundy SM. AHA Conference Proceedings. Prevention conference V (beyond secondary prevention: identifying the high-risk patient for primary prevention: executive summary. American Heart Association). Circulation. 2000;101:111–116
  4. Haffner SM, Lehto S, Ronnemaa T, et al.  Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med. 1998;339:229–234
  5. Bhatt DL, Topol EJ. Antiplatelet and anticoagulant therapy in the secondary prevention of ischemic heart disease. Med Clin North Am. 2000;84:163–179
  6. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. BMJ 2002 ;324:71–86
  7. Sanmuganathan PS, Ghahramani P, Jackson PR, et al.  Aspirin for primary prevention of coronary heart disease (safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials). Heart. 2001;85:265–271
  8. Aspirin for the primary prevention of cardiovascular events: recommendation and rationale. Ann Intern Med 2002 ;136:157–60
  9. Hayden M, Pignone M, Phillips C, et al.  Aspirin for the primary prevention of cardiovascular events (a summary of the evidence for the US Preventive Services Task Force). Ann Intern Med. 2002;136:161–172
  10. Sacks FM, Pfeffer MA, Moye LA, et al.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels (Cholesterol and Recurrent Events Trial Investigators). N Engl J Med. 1996;335:1001–1009
  11. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease (a meta-analysis of randomized controlled trials). JAMA. 1999;282:2340–2346
  12. Yusuf S, Sleight P, Pogue J, et al.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients (the Heart Outcomes Prevention Evaluation Study Investigators). N Engl J Med. 2000;342:145–153
  13. Chan AW, Bhatt DL, Chew DP, et al.  Early and sustained survival benefit associated with statin therapy at the time of percutaneous coronary intervention. Circulation. 2002;105:691–696
  14. Chan AW, Bhatt DL, Chew DP, et al.  Relation of inflammation and benefit of statins after percutaneous coronary interventions. Circulation. 2003;107:1750–1756
  15. CAPRIE Steering Committee . A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet. 1996;348:1329–1339
  16. Bhatt DL, Hirsch AT, Ringleb PA, et al.  Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. Am Heart J. 2000;140:67–73
  17. Bhatt D, Marso S, Hirsch A, et al.  Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol. 2002;90:625–628
  18. Bhatt DL, Chew DP, Hirsch AT, et al.  Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation. 2001;103:363–368
  19. Ringleb PA, Bhatt DL, Hirsch AT, et al.  Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events. Stroke. 2004;35:528–532
  20. Yusuf S, Zhao F, Mehta SR, et al.  Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001;345:494–502
  21. Mehta SR, Yusuf S, Peters RJ, et al.  Effects of pretreatment with clopidogrel and aspirin followed by long- term therapy in patients undergoing percutaneous coronary intervention (the PCI-CURE study). Lancet. 2001;358:527–533
  22. Peters RJ, Mehta SR, Fox KA, et al.  Effects of aspirin dose when used alone or in combination with clopidogrel in patients with acute coronary syndromes (observations from the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) study). Circulation. 2003;108:1682–1687
  23. Topol EJ, Easton D, Harrington RA, et al.  Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation. 2003;108:399–406
  24. Cannon CP, Battler A, Brindis RG, et al.  American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes (a report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee)). J Am Coll Cardiol. 2001;38:2114–2130
  25. GUSTO Investigators . An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med. 1993;329:673–682
  26. Rao AK, Pratt C, Berke A, et al.  Thrombolysis in Myocardial Infarction (TIMI) Trial phase I (hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase). J Am Coll Cardiol. 1988;11:1–11
  27. Bhatt DL, Topol EJ. Need to test the arterial inflammation hypothesis. Circulation. 2002;106:136–140
  28. Ridker PM, Cushman M, Stampfer MJ, et al.  Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med. 1997;336:973–979
  29. Chew DP, Bhatt DL, Robbins MA, et al.  Effect of clopidogrel added to aspirin before percutaneous coronary intervention on the risk associated with C-reactive protein. Am J Cardiol. 2001;88:672–674
  30. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov. 2003;2:15–28
  31. Hermann A, Rauch BH, Braun M, et al.  Platelet CD40 ligand (CD40L) (subcellular localization, regulation of expression, and inhibition by clopidogrel). Platelets. 2001;12:74–82
  32. Quinn M, Bhatt DL, Zidar F, et al. Effect of clopidogrel pretreatment on inflammatory marker expression in patients undergoing percutaneous coronary intervention. Am J Cardiol 2004;93:679–84
  33. Venter JC, Adams MD, Myers EW, et al.  The sequence of the human genome. Science. 2001;291:1304–1351
  34. Topol EJ, McCarthy J, Gabriel S, et al.  Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001;104:2641–2644
  35. Wang L, Fan C, Topol SE, et al.  Mutation of MEF2A in an inherited disorder with features of coronary artery disease. Science. 2003;302:1578–1581
  36. White HD, Simes RJ, Anderson NE, et al.  Pravastatin therapy and the risk of stroke. N Engl J Med. 2000;343:317–326
  37. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals :a randomised placebo-controlled trial. Lancet 2002; 360:7–22
  38. Leon MB, Baim DS, Popma JJ, et al.  A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting (Stent Anticoagulation Restenosis Study Investigators). N Engl J Med. 1998;339:1665–1671
  39. Bhatt DL, Bertrand ME, Berger PB, et al.  Meta-analysis of randomized and registry comparisons of ticlopidine with clopidogrel after stenting. J Am Coll Cardiol. 2002;39:9–14
  40. Bhatt DL, Kapadia SR, Bajzer CT, et al.  Dual antiplatelet therapy with clopidogrel and aspirin after carotid artery stenting. J Invasive Cardiol. 2001;13:767–771
  41. Bhatt DL, Kapadia SR, Yadav JS, et al.  Update on clinical trials of antiplatelet therapy for cerebrovascular diseases. Cerebrovasc Dis. 2000;10(Suppl S5):34–40
  42. Steinhubl SR, Berger PB, Mann JT, et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention (a randomized controlled trial). JAMA. 2002;288:2411–2420
  43. Bhatt DL, Foody JM, Hirsch AT, et al.  Complementary, additive benefit of clopidogrel and lipid-lowering therapy in patients with atherosclerosis. J Am Coll Cardiol. 2000;35(Suppl A):326
  44. Dutch TIA Trial Study Group . A comparison of two doses of aspirin (30 mg vs 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. N Engl J Med. 1991;325:1261–1266
  45. Taylor DW, Barnett HJ, Haynes RB, et al.  Low-dose and high-dose acetylsalicylic acid for patients undergoing carotid endarterectomy (a randomized controlled trial. ASA and Carotid Endarterectomy (ACE) Trial Collaborators). Lancet. 1999;353:2179–2184

☆ Supported by Sanofi-Synthelabo and Bristol-Myers Squibb.

PII: S0002-8703(04)00154-1

doi: 10.1016/j.ahj.2004.03.028

American Heart Journal
Volume 148, Issue 2 , Pages 263-268 , August 2004

Article Tools

* Image Usage & Resolution